Education for NGS Testing in Prostate Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to increase the use of next-generation sequencing (NGS) tests for patients with metastatic prostate cancer at Johns Hopkins. The researchers are testing whether educating doctors and patients can boost the rates of these important genetic tests. The trial includes two groups: one receives educational materials immediately after their first visit, and the other at the end of the study. Men with metastatic prostate cancer who are new patients at Johns Hopkins Medical Oncology in 2025 or 2026 might be a good fit, unless they have already undergone NGS testing. As an unphased trial, this study offers patients the opportunity to contribute to research that could enhance personalized cancer care through education.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that this education protocol is safe for patients with metastatic prostate cancer?
Research has shown that educational programs, like the one in this trial, are generally safe. This study focuses on teaching both doctors and patients about a test called next-generation sequencing (NGS) for prostate cancer. Doctors receive emails about their frequency of using this test, while patients receive handouts or emails explaining NGS testing.
These educational activities carry no known physical risks. They aim to enhance understanding and decision-making. Similar educational programs have reported no negative effects. The goal is to share information so doctors and patients can make informed choices about NGS testing.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it aims to improve prostate cancer care by educating both doctors and patients about Next-Generation Sequencing (NGS) testing. Unlike standard treatments that focus solely on medical interventions, this approach nudges physicians to consider genetic testing through informative emails and provides patients with accessible educational materials. This dual strategy could lead to more personalized treatment plans, ensuring that patients receive the most effective therapies based on their genetic profiles. By increasing awareness and knowledge, this trial could bridge the gap between cutting-edge science and everyday clinical practice, potentially leading to better outcomes for patients.
What evidence suggests that this education method is effective for improving NGS testing rates in prostate cancer?
Research shows that advanced genetic testing, known as next-generation sequencing (NGS), can improve outcomes for prostate cancer patients. Studies have found that using NGS to guide treatment decisions leads to better results. For example, one study discovered that patients lived longer when NGS guided their treatment choices. Another study emphasized that NGS testing provides crucial information that enhances patient care. This trial will explore two approaches: one arm will provide provider nudge and patient education at enrollment, while the other arm will offer provider component and patient education at the study's end. By increasing NGS testing through education, both patients and doctors could benefit from improved treatment outcomes.12678
Who Is on the Research Team?
Catherine Marshall, MD
Principal Investigator
Johns Hopkins University
Are You a Good Fit for This Trial?
This trial is for men diagnosed with metastatic prostate cancer who are new patients at Johns Hopkins Medical Oncology between January 1, 2025 and December 31, 2026.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Enrollment and Education
Provider nudge and patient education at time of enrollment, including a 'nudge' email to physicians and educational material to patients
Follow-up
Participants are monitored for NGS testing rates and receive additional educational material at the end of the study
What Are the Treatments Tested in This Trial?
Interventions
- Provider-level and patient education
Trial Overview
The study aims to increase next-generation sequencing (NGS) testing rates by addressing provider-level and patient-level barriers through education at the end of the study.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
The provider level component (implemented for all patients) will be a "nudge" to physicians to order testing via a single email documenting their NGS testing rate relative to the Johns Hopkins top performer and, for those not in the top 20%, a link to the most recent American Society of Clinical Oncology (ASCO) guidelines recommending testing. In addition, there will be a patient component that is a one-page handout of educational material about NGS testing to be sent after their initial visit via email or mail.
The provider level component (implemented for all patients) will be a "nudge" to physicians to order testing via a single email documenting their NGS testing rate relative to the Johns Hopkins top performer and, for those not in the top 20%, a link to the most recent ASCO guidelines recommending testing. The patient educational material will be provided by email or mail (if no email on file) to those who randomized to this arm.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lead Sponsor
Pfizer
Industry Sponsor
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University
Citations
Usefulness and real-world outcomes of next generation ... - PMC
NGS testing showed an association with improved outcomes in our series when it was performed for either making a therapeutic decision in ...
Barriers to and clinical outcomes with next-generation ...
In this study, we determined the NGS testing rate in M1 prostate cancer at a single academic center and assessed social and clinical features by ...
Physician- and Patient-based Barriers to NGS Testing
The goal of this study is to improve next-generation sequencing (NGS) testing rates at Johns Hopkins in patients with metastatic prostate cancer. Investigators ...
Value of next generation sequencing (NGS) testing in ...
Overall survival was estimated to increase by 0.6 months in prostate cancer, 0.9 months in breast cancer, 3.9 months in NSCLC patients, and 14.2 months in CRC (
A Review of Liquid, Tissue-Based and Combined Next- ...
Next-generation sequencing (NGS) is an invaluable testing method offering clinically significant information to improve patient outcomes.
Potential barriers to implementation of next-generation ... - PMC
The purpose of this study was to identify barriers to physicians' NGS use and preferred strategies to alleviate these barriers.
Race, Ethnicity, and Tumor Genomic Testing in Prostate ...
Tumor next-generation sequencing (NGS) has implications for treatment selection, prognostication, and counseling of patients and is recommended ...
8.
consultqd.clevelandclinic.org
consultqd.clevelandclinic.org/using-next-generation-sequencing-to-target-tumor-genomics-in-metastatic-prostate-cancerUsing Next-Generation Sequencing to Target Tumor ...
Using Next-Generation Sequencing to Target Tumor Genomics in Metastatic Prostate Cancer. Actionability of tumor DNA data remains limited.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.